Dermatology Department, Fattouma Bourguiba Hospital, 5000 Monastir, Tunisia.
Int J Clin Pharm. 2013 Jun;35(3):309-12. doi: 10.1007/s11096-013-9756-1. Epub 2013 Mar 8.
We describe a 55-year-old woman suffering from Sezary syndrome, had undergone chemotherapy consisting of cycles of cyclophosphamide and prednisone. 10 months later, she noticed a progressively increasing reticulated generalised pigmentation in the face, trunk and the extremities. Cylophosphamide was withdrawn. The hyperpigmentation began to clear slowly and gradually after 7 months. One year after cyclophosphamide withdrawal and facing the relapse of the disease, and its transformation to a large T cell lymphoma a mini CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) protocol was held, leading to a remarkable aggravation of the pigmentation.
This adverse drug reaction to cyclophosphamide is peculiar by its localization and distribution and should be known in order not to confuse with other dermatosis.
我们描述了一位 55 岁的女性患有蕈样肉芽肿病,接受了环磷酰胺和泼尼松组成的化疗周期。10 个月后,她注意到面部、躯干和四肢出现逐渐加重的网状泛发性色素沉着。停用环磷酰胺。7 个月后,色素沉着开始缓慢逐渐消退。停用环磷酰胺一年后,疾病复发并转化为大 T 细胞淋巴瘤,给予小剂量 CHOP(环磷酰胺、多柔比星、长春新碱和泼尼松)方案,导致色素沉着明显加重。
这种环磷酰胺的药物不良反应因其定位和分布而具有特殊性,应予以了解,以免与其他皮肤病混淆。